- Analysis of 2 phase 3 UltlMMa-1 and UltlMMa-2 trials shows superior efficacy of risankizumab compared with ustekinumab in patients with moderate-to-severe psoriasis.
Why this matters
- This study supports the use of risankizumab across several patient populations.
- Risankizumab-treated patients scored significantly higher on the PASI90 and sGA 0/1 efficacy measures compared with ustekinumab (P<.001>
- Baseline mean Psoriasis Area and Severity Index (PASI) scores and body surface involvement were similar in both patient groups.
- At week 52, the proportion of patients achieving PASI90 and sGA 0/1 was significantly higher among patients receiving risankizumab compared with patients receiving ustekinumab.
- PASI90 range (77.6%-85.9% in risankizumab vs 30.8%-56.3% in ustekinumab group).
- sGA 0/1 range (79.5%-90.6% in risankizumab vs 39.4%-65.2% in ustekinumab group).
- Results were consistent across all patient subgroups defined by baseline demographics, disease characteristics, and prior biologic response.
- There were no new safety signals in this study, and the adverse event profile was similar in the risankizumab and ustekinumab groups.
- 598 patients received risankizumab and 199 received ustekinumab. The amount of previous biologic therapy was similar in both groups.
- Patients were randomly assigned 3:3:1 to receive risankizumab 150 mg, ustekinumab 45 or 90 mg, or placebo. Patients received injections at weeks 0, 4, 16, 28, and 40 (part A, weeks 0-4).
- At week 16, placebo patients were switched to risankizumab 150 mg.
- Patients received risankizumab or ustekinumab at weeks 16, 28, and 40 (part B, weeks 16-52).
- Funding: AbbVie Inc.